Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Advances in prostate cancer in the last 10 years and a glimpse to the future
Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono
Advances in prostate cancer in the last 10 years and a glimpse to the future ( Prof Laura-Maria Krabbe, Prof Karim Fizazi and Prof Johann De Bono )
21 Oct 2021
WCLC 2021: Epidemiology of MET Exon 14 mutations
Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinge...
WCLC 2021: Epidemiology of MET Exon 14 mutations ( Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger )
19 Oct 2021
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
18 Oct 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera
ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )
11 Oct 2021
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and br...
Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA ( Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA )
6 Oct 2021
ESMO 2021: PARPi data and their role in mono/combination therapies
Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong
ESMO 2021: PARPi data and their role in mono/combination therapies ( Dr Neal Shore, Prof Fred Saad, Prof Eleni Efstathiou, Prof Andrew Armstrong )
29 Sep 2021
ESMO 2021: Updates in hormone-sensitive prostate cancer
Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Cast...
ESMO 2021: Updates in hormone-sensitive prostate cancer ( Prof Eleni Efstathiou, Prof Axel Merseburger, Prof Nicolas Mottet, Dr Elena Castro )
28 Sep 2021
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSC...
Dr Pascale Tomasini and Dr Catherine Shu
Amivantamab combo with lazertinib favourable in post-osimertinib EGFR-mutant NSCLC ( Dr Pascale Tomasini and Dr Catherine Shu )
27 Sep 2021
ESMO 2021: Breast cancer roundup
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2021: Breast cancer roundup ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
27 Sep 2021
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally a...
Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
[Vic-]trastuzumab duocarmazine shows improved PFS in pre-treated HER2+ locally advanced or metastatic breast cancer ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
24 Sep 2021
Drug combination shows promise in treatment-resistant advanced ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Drug combination shows promise in treatment-resistant advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 Sep 2021
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2021